Immune in filtrates are prognostic factors in localized gastrointestinal stromal tumors

Cancer Research

Volumn 73, Issue 12, 2013, Pages 3499-3510

  Rusakiewicz, Sylvie ^a,b,d   Semeraro, Michaela ^a,b,f   Sarabi, Matthieu ^a,b   Desbois, Mélanie ^a,b,d   Locher, Clara ^a,b   Mendez, Rosa ^w   Vimond, Nadège ^a,b,d   Concha, Angel ^w   Garrido, Federico ^w,x   Isambert, Nicolas ^g,h   Chaigneau, Loic ⁱ   Le Brun Ly, Valérie ^j   Dubreuil, Patrice ^g,k,l,m   Cremer, Isabelle ^g,n   Caignard, Anne ^o   Poirier Colame, Vichnou ^a,b,d   Chaba, Kariman ^a,b   Flament, Caroline ^a,b,d   Halama, Niels ^y   Jag̈er, Dirk ^y   Eggermont, Alexander ^a   Bonvalot, Sylvie ^a,e,f   Commo, Fréd́eric ^a,c   Terrier, Philippe ^a,e,f   Opolon, Paule ^a,s   Emile, Jean François ^t   Coindre, Jean Michel ^u   Kroemer, Guido ^a,g,p,q,r   Chaput, Nathalie ^a,b,d   Le Cesne, Axel ^a,d,f   Blay, Jean Yves ^v   Zitvogel, Laurence ^a,b,d,s   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University Paris XI   (France)

^c Universite Paris Sud   (France)

^d CBT 507 Centre of Clinical Investigations   (France)

^e Center of Biological Resources   (France)

^f Department of Oncological Pediatrics ^*  (France)

^g INSERM   (France)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^j DUPUYTREN UNIVERSITY HOSPITAL   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

^m AB Science   (France)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o INSTITUT COCHIN   (France)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q CENTRE DE RECHERCHE DES CORDELIERS   (France)

^r HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^s UNIVERSITÉ PARIS SACLAY   (France)

^t HÔPITAL AMBROISE PARÉ   (France)

^u INSTITUT BERGONIÉ   (France)

^v CENTRE LÉON BÉRARD   (France)

^w HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^x UNIVERSITY OF GRANADA   (Spain)

^y UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PLACEBO; TRANSCRIPTION FACTOR FOXP3; BENZAMIDE DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; NCAM1 PROTEIN, HUMAN; NCR1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; BIOACCUMULATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DENSITY; CELLULAR DISTRIBUTION; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; GASTROINTESTINAL STROMAL TUMOR; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INFLAMMATORY INFILTRATE; KIT GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MIETTINEN SCORE; MUTATIONAL ANALYSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LOCALIZATION; ADULT; AGED; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD56; BENZAMIDES; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84879100801     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0371     Document Type: Article

References (46)

1. Nilsson B, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005;103:821-9. (Pubitemid 40216412)
2. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571.Hum Pathol 2002;33:466-77. (Pubitemid 34747865)
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80. (Pubitemid 28067289)
4. Tuveson DA, Willis NA, Jacks T, Grif fin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054-8. (Pubitemid 32769795)
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6. (Pubitemid 32267975)
6. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
7. Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006;130:1573-81. (Pubitemid 43668833)
8. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10. (Pubitemid 36159485)
9. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2010;108:314-8.
10. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-63. (Pubitemid 39037836)
11. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80. (Pubitemid 34879334)
12. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010;11:942-9.
13. Bardsley MR, Horvath VJ, Asuzu DT, Lorincz A, Redelman D, Hayashi Y, et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010;139:942-52.
14. Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 2011;8:161- 70.
15. Zitvogel L, Kepp O, Kroemer G. Immune parameters affectingthe efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8:151-60.
16. Borg C, Terme M, Taïeb J,Ménard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004;114:379-88. (Pubitemid 39071610)
17. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009;69:3563 -9.
18. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011;17:700-7.
19. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011;17:1094-100.
20. Cameron S, Haller F, Dudas J, Moriconi F, Gunawan B, Armbrust T, et al. Immune cells in primary gastrointestinal stromal tumors. Eur J Gastroenterol Hepatol 2008;20:327-34.
21. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, et al. Anti-infl ammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 2009;127:899-909.
22. Elie N, Plancoulaine B, Signolle JP, Herlin P. A simple way of quantifying immunostained cell nuclei on the whole histologic section. Cytometry A 2003;56:37-45. (Pubitemid 37522504)
23. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007;110:2593-9. (Pubitemid 47523183)
24. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. (Pubitemid 40023952)
25. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356:1795-9.
26. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, et al. Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2010;128:2663-72.
27. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012;72:1070-80.
28. Platonova S,Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, et al. Profound coordinated alterations of intratumora lNK cell phenotype and function in lung carcinoma. Cancer Res 2011;71:5412-22.
29. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008;112:863-75. (Pubitemid 351240580)
30. Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005;175:5790-8. (Pubitemid 41508063)
31. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Due ñas MG, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009;9:186.
32. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 2007;104:267-75. (Pubitemid 47231275)
33. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 2011;71:6621-32.
34. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006;12:718- 25.
35. Da Riva L, Bozzi F, Mondellini P, Miccichè F, Fumagalli E, Vaghi E, et al. Proteomic detection of a large amount of SCGFalpha in the stroma of GISTs after imatinib therapy. J Transl Med 2011;9:158.
36. Hiraoka A, Yano Ki K, Kagami N, Takeshige K, Mio H, Anazawa H, et al. Stem cell growth factor: in situ hybridization analysis on the gene expression, molecular characterization and in vitro proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cells. Hematol J 2001;2:307 -15.
37. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo . Cancer Cell 2002;1: 289-98. (Pubitemid 41039153)
38. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005;202:1075-85.
39. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11: 865-78.
40. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2011;13:265- 74.
41. Ylipää A, Hunt KK, Yang J, Lazar AJ, Torres KE, Lev DC, et al. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 2010;117:380- 9.
42. Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, Tirode F, et al.Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16:781-7.
43. Lagarde P, Pérot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2011;18:826-38.
44. Ricci R, Arena V, Castri F, Martini M,Maggiano N, Murazio M, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004;122:35-43. (Pubitemid 38849870)
45. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005;36:828-37. (Pubitemid 41112040)
46. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2009;15:4191-8.